Skip to main
PALI
PALI logo

Palisade Bio (PALI) Stock Forecast & Price Target

Palisade Bio (PALI) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Palisade Bio Inc is positioned favorably due to its advancement of PALI-2108, a promising candidate for treating autoimmune diseases, particularly ulcerative colitis (UC), where there is a significant unmet medical need. The company has reported encouraging pre-clinical data showcasing PALI-2108’s anti-inflammatory effects and tolerability, specifically highlighting its anti-TNF activity and substantial reductions in inflammatory markers. With the stock showing a positive upward trend and the prospect of addressing a niche market for oral PDE4 therapies, the outlook for Palisade Bio's stock appears strong based on these developments.

Bears say

Palisade Bio Inc faces significant financial challenges, including a lack of commercial infrastructure that hampers its ability to bring products to market. The company is currently not profitable and may require additional capital, which raises concerns about potential dilution for existing investors. Furthermore, both the company and its auditors have expressed substantial doubt regarding its ability to continue as a going concern, exacerbating the already precarious financial situation.

Palisade Bio (PALI) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Palisade Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Palisade Bio (PALI) Forecast

Analysts have given Palisade Bio (PALI) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Palisade Bio (PALI) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Palisade Bio (PALI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.